 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
Evaluation of phenotypic and genotypic drug susceptibility testings for pyrazinamide |
| Language |
J |
| AuthorList |
Akio Aono, Kinuyo Chikamatsu, Yuriko Igarashi, Akiko Takaki, Hiroyuki Yamada, Satoshi Mitarai |
| Affiliation |
Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-tuberculosis Association, kiyose, Japan |
| Publication |
J.J.C.M.: 25 (4), 314-319, 2015 |
| Received |
May 26, 2015 |
| Accepted |
June 22, 2015 |
| Abstract |
Pyrazinamide (PZA) is the key drug for the treatment of tuberculosis. The inconsistencies between pyrazinamidase (PZAse) test, PZA drug susceptibility testing (DST) and pncA gene sequencing method are reported recently. In this study, we compared those three methods using 77 strains of multidrug-resistant Mycobacterium tuberculosis and investigated discrepant strains in detail. We performed KYOKUTO PZA and MGIT PZA tests and pncA gene sequencing, and compered the results with PZAse tests as referral. KYOKUTO PZA showed 88.1%, 85.7%, 87.0% and 0.77 of sensitivity, specificity, agreement and Kappa coefficient, respectively. Similarly, MGIT PZA showed 100%, 80.0%, 90.9% and 0.81, respectively. The mutations of pncA gene indicated 100%, 97.1%,98.7% and 0.97, respectively. The highest agreement was observed between pncA gene sequencing method and PZAse test. In this study, current phenotypic DST methods were less accurate than genotypic method. The sequencing of pncA or equivalent test shall be encouraged for the accurate PZA susceptibility. |
| Keywords |
pyrazinamidase |
|
